About this trial
Sensory neuronopathies (also called sensory ganglionopathies) are rare and heterogeneous disorders of genetic or acquired origin, caused by degeneration of the dorsal root ganglia. Their diagnosis currently relies on a combination of clinical evaluation and electrophysiological testing, as no specific biomarker is available.
Early diagnosis is particularly important in acquired forms, where early treatment can significantly influence prognosis.
Recent studies have reported a characteristic ultrasound pattern in several genetic sensory neuronopathies, showing abnormally small-caliber peripheral nerves in the upper limbs. However, these findings have only been described in genetic conditions. It is therefore unknown whether this ultrasound pattern is specific to genetic causes or may also occur in acquired sensory neuronopathies, especially those with long-standing evolution.
This retrospective multicenter study will analyze data already collected as part of routine care in approximately 50 patients with sensory neuronopathy. The objective is to compare nerve ultrasound findings between genetic and acquired forms, and to evaluate their association with clinical severity and electrophysiological parameters. Determining whether nerve atrophy observed on ultrasound is specific to genetic etiologies could help integrate ultrasound into the diagnostic workup, guiding the choice of complementary tests such as genetic analyses or early treatment initiation in acquired cases.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Sensory ganglionopathy diagnosed according to the criteria of Camdessanché et al.
Nerve ultrasound performed as part of routine clinical care.
Age > 18 years.
Disqualifiers
Comorbid conditions that may interfere with the interpretation of sensory ganglionopathy.
Lack of consent (patient opposition to the use of clinical data for research).
Trial population
Adult patients diagnosed with sensory neuronopathy according to Camdessanché criteria, who underwent nerve ultrasound as part of routine clinical care. Patients are retrospectively identified from medical records across four French tertiary neurology centers between 2024 and 2025, including both acquired and genetic etiologies.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Cross-sectional area of peripheral nerves according to ganglionopathy etiology (genetic vs acquired)
Measurement of the cross-sectional area (mm²) of peripheral nerves on ultrasound (median nerve at forearm and arm, ulnar nerve at forearm and arm, sural nerve at ankle, radial sensory nerve at distal forearm, C5 and C6 roots at foraminal emergence, and vagus nerve at mid-cervical level) to compare nerve caliber between patients with genetic versus acquired sensory ganglionopathies
Secondary outcomes
Correlation between nerve cross-sectional area and clinical severity
Assessment of the association between peripheral nerve cross-sectional area (mm²) and clinical variables, including duration of symptoms (months) and severity of proprioceptive ataxia (Mariette score, 0-3)
Correlation between nerve cross-sectional area and electrophysiological severity
Assessment of the association between peripheral nerve cross-sectional area (mm²) and electrophysiological parameters, including sensory nerve action potential amplitudes (sural and radial nerves, µV) and other available electrophysiological measures relevant to axonal loss
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: